Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd

₹ 106 0.46%
14 Nov - close price
About

Incorporated in 1977, Mangalam Drugs
& Organics Ltd manufactures Active Pharmaceutical Ingredients and
Intermediates[1]

Key Points

Business Overview:[1]
Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations

  • Market Cap 167 Cr.
  • Current Price 106
  • High / Low 145 / 85.2
  • Stock P/E 17.7
  • Book Value 93.2
  • Dividend Yield 0.00 %
  • ROCE 1.19 %
  • ROE -6.12 %
  • Face Value 10.0

Pros

  • Stock is trading at 1.13 times its book value
  • Debtor days have improved from 37.0 to 27.7 days.

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 10.1% over past five years.
  • Company has a low return on equity of 2.70% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
123.02 101.88 120.96 109.49 108.33 63.32 91.11 87.46 81.56 97.34 102.24 76.53 79.94
109.26 87.56 110.77 99.12 99.89 56.84 90.87 90.94 79.37 90.36 90.54 68.34 71.25
Operating Profit 13.76 14.32 10.19 10.37 8.44 6.48 0.24 -3.48 2.19 6.98 11.70 8.19 8.69
OPM % 11.19% 14.06% 8.42% 9.47% 7.79% 10.23% 0.26% -3.98% 2.69% 7.17% 11.44% 10.70% 10.87%
0.00 0.00 0.00 0.01 0.00 0.13 0.29 0.02 0.03 0.00 0.05 0.02 0.14
Interest 2.98 2.69 2.53 3.54 2.56 3.22 3.43 3.41 3.24 3.31 3.95 3.75 3.67
Depreciation 2.50 2.67 2.69 2.60 2.76 2.88 2.75 3.42 3.73 3.62 3.86 3.87 3.97
Profit before tax 8.28 8.96 4.97 4.24 3.12 0.51 -5.65 -10.29 -4.75 0.05 3.94 0.59 1.19
Tax % 45.41% 55.02% -34.61% 29.01% 28.85% 15.69% -22.30% -7.29% -25.05% -920.00% 9.90% -355.93% -125.21%
4.53 4.02 6.69 3.00 2.23 0.43 -4.39 -9.54 -3.56 0.50 3.55 2.68 2.69
EPS in Rs 2.86 2.54 4.23 1.90 1.41 0.27 -2.77 -6.03 -2.25 0.32 2.24 1.69 1.70
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
124 123 221 295 299 269 228 282 380 451 372 369 356
129 113 200 257 252 222 218 259 327 402 347 351 320
Operating Profit -4 10 20 38 47 47 10 24 53 49 26 17 36
OPM % -4% 8% 9% 13% 16% 17% 4% 8% 14% 11% 7% 5% 10%
2 0 0 0 -0 1 0 1 5 0 0 0 0
Interest 10 10 10 9 10 12 9 10 9 11 13 14 15
Depreciation 4 4 4 4 5 7 7 8 9 10 11 15 15
Profit before tax -17 -4 6 24 31 29 -6 6 40 28 2 -11 6
Tax % -30% -22% -2% 33% 29% 32% 40% -32% 29% 29% 43% -18%
-12 -3 6 16 22 20 -8 8 28 20 1 -9 9
EPS in Rs -8.95 -2.31 4.66 11.15 14.08 12.57 -5.07 5.21 17.67 12.42 0.80 -5.72 5.95
Dividend Payout % 0% 0% 0% 0% 0% 4% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 12%
5 Years: 10%
3 Years: -1%
TTM: 10%
Compounded Profit Growth
10 Years: %
5 Years: -3%
3 Years: %
TTM: 155%
Stock Price CAGR
10 Years: 16%
5 Years: 27%
3 Years: -8%
1 Year: 7%
Return on Equity
10 Years: 11%
5 Years: 7%
3 Years: 3%
Last Year: -6%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 13 13 13 14 16 16 16 16 16 16 16 16 16
Reserves 13 10 16 39 70 88 80 88 115 135 136 127 132
73 77 78 60 66 69 65 52 70 88 89 106 83
16 25 63 47 38 54 50 75 64 90 117 109 150
Total Liabilities 115 125 170 160 190 227 211 231 264 328 358 357 380
55 53 53 54 93 102 103 101 118 135 142 147 154
CWIP 0 0 0 5 0 0 0 1 6 6 9 8 0
Investments 0 0 0 0 2 0 0 0 0 0 0 0 0
59 72 117 100 95 125 107 128 140 188 206 202 227
Total Assets 115 125 170 160 190 227 211 231 264 328 358 357 380

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-1 7 14 22 43 25 22 31 28 26 38 12
-2 -2 -4 -11 -39 -16 -9 -7 -31 -27 -22 -18
2 -5 -10 -11 -3 -9 -11 -23 3 3 -17 6
Net Cash Flow -1 0 1 -0 0 -0 1 0 -1 1 -1 -0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 70 88 73 37 45 61 28 52 52 38 46 28
Inventory Days 112 170 134 85 69 132 175 121 85 139 200 185
Days Payable 39 97 128 37 38 82 77 106 63 65 139 124
Cash Conversion Cycle 144 161 79 85 75 111 126 67 74 112 107 88
Working Capital Days 125 122 79 76 70 99 102 66 75 84 93 97
ROCE % -7% 6% 16% 30% 32% 25% 2% 11% 27% 18% 6% 1%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
50.53% 50.53% 50.42% 50.41% 50.31% 50.31% 50.31% 50.31% 50.31% 50.31% 50.31% 50.30%
0.00% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.26% 0.21% 0.11%
0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
49.46% 49.36% 49.47% 49.49% 49.58% 49.59% 49.58% 49.59% 49.59% 49.42% 49.47% 49.58%
No. of Shareholders 20,66820,08418,98818,48317,91117,94317,89017,97818,61019,17319,31219,508

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls